A compound of Formula III, IV or A-1, or a pharmaceutically acceptable salt thereof, for use in therapeutically treating one of the following: (i) an adipose condition in a subject wherein the treatment comprises a) non-surgical reduction or removal of one or more localized fat deposits in a subject having localized fat accumulation and wherein the compound is to be administered to a target site in the fat deposit; b) reducing a subcutaneous fat deposit in a subject having a subcutaneous fat deposit, wherein the compound is to be administered to a target site in the subcutaneous fat deposit; or c) decreasing a submental fat deposit under a skin area in a subject, wherein the compound is to be administered to a target site in the fat deposit; (ii) an adipose tissue disorder or an adipose tissue tumor in a subject, wherein the compound is to be locally administered to the subject; or (iii) sleep apnea in a subject, wherein the compound is to be locally administered and the sleep apnea is caused by a fat deposit around a trachea in the subject, and the compound is to be administered to the fat deposit around the trachea; wherein Formula III is represented by: wherein R 1 is hydrogen, C 1-6 alkyl, or hydroxy; R 2, R 3, R 4, R 6, and R 7 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, substituted amino, halogen, -(CH 2) x -C -OC 1-6 alkyl, -(CH 2) x -OH, -(CH 2) x -CN, -OCH 2 C 6 H 5, -CHO, -(CH 2) x -COOH, -(CH 2) x -COOC 1-6 alkyl, -(CH 2) y -CO-COOH, and - (CH 2) y -C -COOH; R 5 is bromo x is a number from zero to six; and y is a number from zero to six; Formula is represented by: wherein R 1 is hydrogen, C 1-6 alkyl, or hydroxy; R 2, R 3, R 4, R 5, R 6, and R 7 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, substituted amino, halogen, -(CH 2) x -C -OC 1-6 alkyl, -(CH 2) x -OH, -(CH 2) x -CN, -OCH 2 C 6 H 5, -CHO, -(CH 2) x -COOH, -(CH 2) x -COOC 1-6 alkyl, -(CH 2) y -CO-COOH, and - (CH 2) y -C -COOH; x is a number from zero to six; and y is a number from zero to six; provided that at least one of R 2, R 3, R 4, R 5, R 6, and R 7 is -CHO; Formula (A-1) is represented by wherein the term C 1-6 alkyl refers to a monovalent saturated aliphatic hydrocarbyl group having from 1 to 6 carbon atoms. (i) an adipose condition in a subject wherein the treatment comprises a) non-surgical reduction or removal of one or more localized fat deposits in a subject having localized fat accumulation and wherein the compound is to be administered to a target site in the fat deposit; b) reducing a subcutaneous fat deposit in a subject having a subcutaneous fat deposit, wherein the compound is to be administered to a target site in the subcutaneous fat deposit; or c) decreasing a submental fat deposit under a skin area in a subject, wherein the compound is to be administered to a target site in the fat deposit; a) non-surgical reduction or removal of one or more localized fat deposits in a subject having localized fat accumulation and wherein the compound is to be administered to a target site in the fat deposit; b) reducing a subcutaneous fat deposit in a subject having a subcutaneous fat deposit, wherein the compound is to be administered to a target site in the subcutaneous fat deposit; or c) decreasing a submental fat deposit under a skin area in a subject, wherein the compound is to be administered to a target site in the fat deposit; (ii) an adipose tissue disorder or an adipose tissue tumor in a subject, wherein the compound is to be locally administered to the subject; or (iii) sleep apnea in a subject, wherein the compound is to be locally administered and the sleep apnea is caused by a fat deposit around a trachea in the subject, and the compound is to be administered to the fat deposit around the trachea; R 1 is hydrogen, C 1-6 alkyl, or hydroxy; R 2, R 3, R 4, R 6, and R 7 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, substituted amino, halogen, -(CH 2) x -C -OC 1-6 alkyl, -(CH 2) x -OH, -(CH 2) x -CN, -OCH 2 C 6 H 5, -CHO, -(CH 2) x -COOH, -(CH 2) x -COOC 1-6 alkyl, -(CH 2) y -CO-COOH, and - (CH 2) y -C -COOH; R 5 is bromo x is a number from zero to six; and y is a number from zero to six; R 1 is hydrogen, C 1-6 alkyl, or hydroxy; R 2, R 3, R 4, R 5, R 6, and R 7 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, substituted amino, halogen, -(CH 2) x -C -OC 1-6 alkyl, -(CH 2) x -OH, -(CH 2) x -CN, -OCH 2 C 6 H 5, -CHO, -(CH 2) x -COOH, -(CH 2) x -COOC 1-6 alkyl, -(CH 2) y -CO-COOH, and - (CH 2) y -C -COOH; x is a number from zero to six; and y is a number from zero to six; provided that at least one of R 2, R 3, R 4, R 5, R 6, and R 7 is -CHO;